argenx SE (ARGX)

NASDAQ: ARGX · USD

$892

+9.35 (+1.1%)· Recorded snapshot

영어 원본으로 대체KO

번역하는 동안 영어 원본을 표시 중

이 리포트는 아직 번역되지 않았습니다. 번역 대기열이 따라잡으면 몇 분 후에 새로고침하세요.

StockMarketAgent Research · Analyzed 2026-05-20

Our latest published analysis: ARGX rated Strong Buy

argenx SE's published Strong Buy conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.

Fair value

$1,486 / share

Potential value

$2,709 / share

Upside to FV

+86.3%

from $892

Moat

6.5/10

Narrow

Read full analysis →View archive · 24mo

9-phase methodology · same model in each published edition

Market cap	$49.9B
Revenue (ttm)	5.9B
Net income (ttm)	1.9B
EPS (ttm)	$28.3
Shares out	62.7M
P/E (trailing)	31.5x
P/E (forward)	21.8x
Volume	171,472
Beta	-0.04

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 5.9B
Net income (ttm): 1.9B
EPS (ttm): $28.3
P/E (trailing): 31.5x
P/E (forward): 21.8x
Market cap: $49.9B

Item	P1	P2	P3	P4	Trend
Period	2022-12-31	2023-12-31	2024-12-31	2025-12-31	Trend
Revenue	$410.7M	$1.23B	$2.19B	$4.15B	+116.2%
Gross profit	$381.3M	$1.11B	$1.96B	$3.70B	+113.3%
Operating income	$-727.1M	$-303.6M	$87.6M	$1.28B	—
Net income	$-709.6M	$-295.1M	$833.0M	$1.29B	—
EPS (diluted)	$-13.05	$-5.16	$12.78	$19.57	—
EBITDA	$-622.8M	$-192.3M	$105.2M	$1.31B	—
R&D	$663.4M	$859.5M	$983.4M	$1.36B	+27.2%
SG&A	$469.9M	$709.5M	$1.05B	$1.36B	+42.5%

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ALNY	Alnylam Pharmaceuticals, Inc.	31.1B	41.4x	6.4x	96.6%	+47.5%	-52.1%	적극 매수
AXON	Axon Enterprise Inc.	34.4B	176.1x	10.6x	1.2%	+31.9%	-43.4%	매도
COIN	Coinbase Global, Inc.	42.8B	—	7.0x	4.1%	+4.2%	-55.8%	매도
ABBV	AbbVie Inc.	505.6B	80.8x	7.9x	17.7%	+3.7%	+29.1%	매도
ABT	Abbott Laboratories	177.6B	38.2x	3.7x	7.2%	+2.7%	-17.2%	비중 축소
ALGN	Align Technology Inc.	10.9B	26.6x	2.6x	17.2%	+3.6%	+11.6%	비중 축소

Base and Bull scenarios

Bull25%

Price target

$2,709.48

+239.6% from spot

VYVGART achieves standard-of-care status in 5+ indications simultaneously, driving margins toward 40%+.

Standard-of-care in 5+ indications
Operating margins expand beyond 40%

Base50%

Price target

$1,486.48

+86.3% from spot

Solid execution in gMG and CIDP with steady margin expansion towards the 30% target.

22.5% Year 1 growth
30% terminal operating margin

Sensitivity: Ke × terminal growth

The highlighted base cell is anchored to valuation synthesis sensitivity reference ($1,486.48). It is the reference value for this grid, not a separate standalone fair-value claim.

Ke ↓ / g →	2.5%	3.0%	3.5%	4.0%	4.5%
6.4%	$1,871	$2,148	$2,522	$2,601	$2,601
7.4%	$1,486	$1,657	$1,871	$2,148	$2,522
8.4%	$1,233	$1,348	$1,486	$1,657	$1,871
9.4%	$1,054	$1,136	$1,233	$1,348	$1,486
10.4%	$920	$982	$1,054	$1,136	$1,233

Scorecard

Published factor rows and weighted composite

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E21.8

P25 n/aP50 n/aP75 n/a

Trailing P/E35.4

P25 n/aP50 n/aP75 n/a

ROE23.6

P25 n/aP50 n/aP75 n/a

ROIC57

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All ARGX indicators

Market & fundamental data

Available fields

227

Groups with data

Currency

USD

Showing 227 of 227 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001697862
Company name	argenx SE
Country	Netherlands
Country code	US
CUSIP number	04016X101
Earnings date	2026-10-22
Earnings time	bmo
Employees	1,863
Employees change	264
Employees growth	16.51%
Enterprise value	$51.1B
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-09-30
First seen	2026-05-09
Fiscal year end	December
Founded	2008
Industry	Biotechnology
IPO date	2017-05-18
Is primary listing	No
Is SPAC	No
ISIN number	US04016X1019
Last 10-K release date	2026-03-19
Last earnings date	2026-10-22
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$56.1B
Market cap category	Large-Cap
Next earnings date	2027-02-25
Options	Yes
Price	$891.80
Price currency	USD
Sector	Healthcare
SIC code	2836
Stock price date	2026-10-28
Symbol	ARGX
Website	https://argenx.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Adjusted P/E ratio	31.12x
Average P/E ratio (3Y)	33.67x
Earnings yield	3.18%
EV/Earnings	26.9x
EV/EBIT	26.72x
EV/EBITDA	26.56x
EV/FCF	52.04x
EV/Sales	8.53x
FCF / EV yield	1.92%
FCF yield	1.75%
Forward EV/Sales	6.43x
Forward P/E	25.79x
Forward P/S	7.07x
Graham number	301.24065
Graham upside	-66.04%
P/(FCF - SBC) ratio	77.56x
P/(OCF - SBC) ratio	77.11x
P/B ratio	6.6x
P/E ratio	31.49x
P/FCF ratio	57.24x
P/OCF ratio	57x
P/S ratio	9.39x
Price / tangible book value	6.81x
Price/EBITDA ratio	29.21x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	31.94%
EBITDA margin	32.14%
Effective tax rate	1.14%
FCF margin	18.25%
Gross margin	59.84%
Operating margin	31.94%
Pretax margin	32.1%
Profit margin	31.73%
Profit per employee	$1M
Profitable years	2
Revenue per employee	$3.2M
ROA	11.63%
ROA (5Y)	-4.42%
ROCE	18.94%
ROE	23.64%
ROE (5Y)	-3.39%
ROIC	56.96%
SBC / revenue	4.78%
Tax / revenue	0.36%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth	24.08%
EPS growth (Q)	50.58%
EPS growth (QoQ)	6.85%
EPS growth years	3
FCF growth	143.78%
Gross profit growth	75.23%
Gross profit growth (Q)	57.81%
Gross profit growth 3Y	146.42%
Net income growth	22.42%
Net income growth (Q)	46.98%
Net income growth (QoQ)	7.2%
Net income growth years	3
OCF growth	141.19%
OCF growth 10Y	51.21%
Operating income growth	137.21%
Operating income growth (Q)	81.44%
Revenue growth	60.6%
Revenue growth (Q)	52.08%
Revenue growth (QoQ)	13.63%
Revenue growth 10Y	79.47%
Revenue growth 3Y	79.16%
Revenue growth 5Y	63.26%
Revenue growth years	3

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-4.2M
Depreciation and amortization	$11.5M
EBIT	$1.9B
EBITDA	$1.9B
EPS	$28.32
FCF per share	$15.46
Financing cash flow	$264M
Free cash flow	$970M
Free cash flow minus SBC	$715.9M
Gross profit	$3.5B
Income taxes	$21.6M
Investing cash flow	$264M
Net borrowing	$-10.1M
Net cash flow	$1.5B
Net income	$1.9B
Operating cash flow minus SBC	$720.1M
Operating income	$1.9B
Revenue	$5.9B
Stock-based compensation	$254.1M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Book value per share	$134.59
Debt / EBITDA	0.02
Debt / equity	0.01
Debt / FCF	0.05
Interest coverage	595.15
Net cash (debt)	$5.1B
Net cash / market cap	9.25%
Net cash growth	32.23%
Net debt / EBITDA	-2.7
Net debt / equity	-0.61
Net debt / FCF	-5.3
Piotroski F-Score	5
Shareholders' equity	$8.4B
Tangible book value	$8.2B
Tangible book value per share	$130.34
Total cash	$5.2B
Total debt	$47M
WACC	4.02%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.62
Current ratio	5.12
Inventory turnover	6.12
Quick ratio	4.52
Working capital	$6.5B

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	1.31%
Dividend yield	0%
Shareholder yield	1.31%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$876.65
1D price change	1.06%
1M price change	-7.05%
1M total return	-7.05%
1W price change	0.2%
1W total return	0.2%
1Y price change	7.47%
1Y return CAGR	7.47%
1Y total return	7.47%
20-day SMA	$867.39
200-day SMA	$853.83
3M price change	0.34%
3M total return	0.34%
3Y price change	93.92%
3Y return CAGR	24.7%
3Y total return	93.92%
50-day SMA	$949.22
50-day SMA vs 200-day SMA	50over200
52-week high	$1,072.75
52-week high date	2026-09-02
52-week low	$661.85
52-week low date	2026-03-20
5Y price change	218.98%
5Y return CAGR	26.12%
5Y total return	218.98%
6M price change	13.79%
6M total return	13.79%
All-time high	$1,072.75
All-time high date	2026-09-02
All-time low	$17.33
All-time low date	2017-05-18
Average true range (ATR)	$30.04
Average volume	506.3K
Beta (5Y)	-0.04
Change from 52-week high	-16.87%
Change from 52-week low	34.74%
Change from all-time high	-16.87%
Change from all-time low	5,045.99%
Change from open	0.96%
Day's gap	0.09%
Dollar volume	$152.9M
High price	$896.91
Low price	$882.27
Monthly RSI	59.06
Open price	$883.31
Position in 52-week range	65.1%
Premarket change	-0.55%
Premarket close	$882.48
Premarket price	$877.67
Premarket volume	152
Previous close	$882.48
Price vs 150-day SMA	1.73%
Price vs 20-day SMA	2.81%
Price vs 200-day SMA	4.45%
Price vs 50-day SMA	-6.05%
Relative volume	0.34
RSI	50.27
Sharpe ratio	0.27
Sharpe ratio (3Y)	0.64
Sharpe ratio (5Y)	0.65
Sortino ratio	0.58
Sortino ratio (3Y)	1.07
Sortino ratio (5Y)	1.15
Volume	171.5K
Weekly RSI	50.9
YTD price change	6.05%
YTD total return	6.05%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	62.4M
Float percentage	99.52%
Shares change (QoQ)	0.56%
Shares change (YoY)	-1.31%
Shares held by insiders	0.17%
Shares held by institutions	75.67%
Shares outstanding	62.7M
Short % of shares	2.16%
Short ratio	5.5 days

Deeper analysis on ARGX

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Quote this valuation with its source: Fair value, Potential value and the price at analysis.

Frequently asked questions

About this ARGX report

What is the latest published ARGX stock rating?

argenx SE is shown with Strong Buy in the latest published report, analyzed 2026-05-20. The hub links directly to the full analysis surface where the dated rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full ARGX analysis?

The full latest published report, analyzed 2026-05-20, lives at /stocks/ARGX/analysis. The bare ticker page summarizes that read and links to each analysis tab; earlier editions remain under /analysis/archive.

What fair value is used for ARGX?

The latest published report analyzed 2026-05-20 gives ARGX a fair value of USD 1,486 and a potential value of USD 2,709. These are dated research outputs, not live market prices; review the valuation assumptions, sensitivity analysis, and material risks before making a decision.

How often is the ARGX page updated?

The hub selects the latest published stock report regardless of age and displays its analysis date (2026-05-20). Separately sourced market data is labeled with its own recorded timestamp and is never inferred from the report.

Strong BuyARGX · Fair value $1,486+86.3%

Read full analysis →

argenx SE (ARGX)

Our latest published analysis: ARGX rated Strong Buy

Price

Financial snapshot

Fair-value bridge

Latest news · ARGX

Valuation

Profitability

Balance sheet

Trading

Base and Bull scenarios

Sensitivity: Ke × terminal growth

Scorecard

Next earnings

Sector percentile context

All ARGX indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on ARGX

Frequently asked questions

등급 이력

Category	Score	Reading
Valuation	9.5
Management	6.9
Balance Sheet	7.0
Profitability	6.5
Revenue Growth	9.0
Risk Assessment	8.5
Competitive Moat	6.5
Earnings Quality	6.5
Capital Efficiency	6.5